AIM: To investigate the in vitro effect of entecavir (ETV on the function of dendritic cells (DCs) derived from chronic hepatitis B (CHB) patients. METHODS: Mononuclear cells were isolated from peripheral blood of pat...AIM: To investigate the in vitro effect of entecavir (ETV on the function of dendritic cells (DCs) derived from chronic hepatitis B (CHB) patients. METHODS: Mononuclear cells were isolated from peripheral blood of patients with CHB. DCs wer incubated with RPMI-1640 medium supplemented wit fetal bovine serum, IL-4, granulocyte-macrophag colony-stimulating factor (GM-CSF). DCs were treate with or without ETV on the fourth day. Cell surfac molecules, including CD1a, CD80, CD83 and HLA-DR were assessed by flow cytometry. Concentrations of IL- and IL-12 in the supernatant were assayed by enzyme linked immunosorbent assay (ELISA). The ability of th generated DCs to stimulate lymphocyte proliferation wa observed. RESULTS: Compared with CHB control group, th expression levels of CD1a (29.07 ± 3.20 vs 26.85 ± 2.80 CD83 (25.66 ± 3.19 vs 23.21 ± 3.10), CD80 (28.00 ± 2.7 vs 25.75 ± 2.51) and HLA-DR (41.96 ± 3.81 vs 32.20 ± 3.04) in ETV-treated group were higher (P < 0.05). ETV treated group secreted significantly more IL-12 (157.6 ± 26.85 pg/mL vs 132.60 ± 22.00 pg/mL (P < 0.05) an had a lower level of IL-6 in the culture supernatant (83.0 ± 13.88 pg/mL vs 93.60 ± 13.61 pg/mL, P < 0.05) tha CHB control group. The ability of DCs to stimulate th proliferation of allogeneic lymphocytes was increase in ETV-treated group compared with CHB control grou (1.53 ± 0.09 vs 1.42 ± 0.08, P < 0.05).CONCLUSION: Entecavir can enhance the biological activity of DCs derived from CHB patients.展开更多
AIM： To investigate if the nucleoside analogue lamivudine （LAM）, a potent inhibitor of HBV replication, could restore the function of dendritic cells derived from patients with chronic hepatitis B （CHB） in an Asi...AIM： To investigate if the nucleoside analogue lamivudine （LAM）, a potent inhibitor of HBV replication, could restore the function of dendritic cells derived from patients with chronic hepatitis B （CHB） in an Asian population.METHODS： Dendritic cells （DCs） derived from mononuclearcytes of patients with chronic HBV infection were cultured in the presence of IL-4, granulocytemacrophage colony-stimulating factors （GM-CSF） and gradient concentrations of LAM （0-2 mmol/L）. Cell morphology was observed under light microscopy. Cell surface molecules, including HI_A-DR, CD80, CD83, and CDla, were analyzed with flow cytometry. The concentrations of IL-6 and IL-12 in the supernatant were assayed by ELISA. T cell proliferation was assayed by methyl thiazoM tetrazolium （MTT）.RESULTS： The expression of CDlα on DC treated with 0.5 mmol/L LAM （LAM-DC 0.5 mmol/L） was significantly higher than that of DC untreated with LAM （54.1 ± 4.21 vs 33.57 ± 3.14, P 〈 0.05）, and so was the expression of CD83 （20.24 ± 2.51 vs 12.83 ± 2.12, P 〈 0.05） as well as the expression of HLA-DR （74.5 ± 5.16 vs 52.8 ± 2.51, P 〈 0.05）. Compared with control group, LAM-DC group （0.5 mmol/L） secreted significantly more IL-12 （910 ± 91.5 vs 268 ± 34.3 pg/mL, P 〈 0.05）, had lower levels of IL-6 in the culture supernatant （28 ± 2.6 vs 55 ± 7.36 pg/mL, P 〈 0.05）, markedly enhanced the stimulatory capacity in the allogeneic mixed leukocyte reaction （MLR） （1.87 ± 0.6 vs 1.24 ± 0.51, P 〈 0.05）.CONCLUSION： The lower expression of phenotypic molecules and impaired allogeneic mixed lymphocyte reaction function of dendritic cells derived from patients with HBV infection could be restored in vitro by incubation with LAM.展开更多
在脑卒中幸存者中,卒中后认知障碍(Post-stroke cognitive impairment,PSCI)是导致残疾的主要原因之一,目前临床治疗多聚焦于药物治疗而其他干预手段有限。经颅直流电刺激(Transcranial direct current stimulation,tDCS)是一种无创的...在脑卒中幸存者中,卒中后认知障碍(Post-stroke cognitive impairment,PSCI)是导致残疾的主要原因之一,目前临床治疗多聚焦于药物治疗而其他干预手段有限。经颅直流电刺激(Transcranial direct current stimulation,tDCS)是一种无创的神经调控技术,广泛用于各种认知障碍的康复治疗,但其作用机制尚不明确。本文结合近年来国内外研究,概括了PSCI发病机制、tDCS治疗认知障碍的作用机制。文献复习结果表明,tDCS可能通过改善脑部神经-血管耦合、调节皮质兴奋性、促进突触可塑性、加强脑区间的功能连接等机制达到改善PSCI的效果。这些结果可以为PSCI及卒中后其他功能障碍的临床康复治疗提供理论依据。未来,还能基于“脑-肢协同治疗技术”理论,将tDCS与其他外周干预手段相结合,使其发挥最佳疗效。展开更多
文摘AIM: To investigate the in vitro effect of entecavir (ETV on the function of dendritic cells (DCs) derived from chronic hepatitis B (CHB) patients. METHODS: Mononuclear cells were isolated from peripheral blood of patients with CHB. DCs wer incubated with RPMI-1640 medium supplemented wit fetal bovine serum, IL-4, granulocyte-macrophag colony-stimulating factor (GM-CSF). DCs were treate with or without ETV on the fourth day. Cell surfac molecules, including CD1a, CD80, CD83 and HLA-DR were assessed by flow cytometry. Concentrations of IL- and IL-12 in the supernatant were assayed by enzyme linked immunosorbent assay (ELISA). The ability of th generated DCs to stimulate lymphocyte proliferation wa observed. RESULTS: Compared with CHB control group, th expression levels of CD1a (29.07 ± 3.20 vs 26.85 ± 2.80 CD83 (25.66 ± 3.19 vs 23.21 ± 3.10), CD80 (28.00 ± 2.7 vs 25.75 ± 2.51) and HLA-DR (41.96 ± 3.81 vs 32.20 ± 3.04) in ETV-treated group were higher (P < 0.05). ETV treated group secreted significantly more IL-12 (157.6 ± 26.85 pg/mL vs 132.60 ± 22.00 pg/mL (P < 0.05) an had a lower level of IL-6 in the culture supernatant (83.0 ± 13.88 pg/mL vs 93.60 ± 13.61 pg/mL, P < 0.05) tha CHB control group. The ability of DCs to stimulate th proliferation of allogeneic lymphocytes was increase in ETV-treated group compared with CHB control grou (1.53 ± 0.09 vs 1.42 ± 0.08, P < 0.05).CONCLUSION: Entecavir can enhance the biological activity of DCs derived from CHB patients.
文摘AIM： To investigate if the nucleoside analogue lamivudine （LAM）, a potent inhibitor of HBV replication, could restore the function of dendritic cells derived from patients with chronic hepatitis B （CHB） in an Asian population.METHODS： Dendritic cells （DCs） derived from mononuclearcytes of patients with chronic HBV infection were cultured in the presence of IL-4, granulocytemacrophage colony-stimulating factors （GM-CSF） and gradient concentrations of LAM （0-2 mmol/L）. Cell morphology was observed under light microscopy. Cell surface molecules, including HI_A-DR, CD80, CD83, and CDla, were analyzed with flow cytometry. The concentrations of IL-6 and IL-12 in the supernatant were assayed by ELISA. T cell proliferation was assayed by methyl thiazoM tetrazolium （MTT）.RESULTS： The expression of CDlα on DC treated with 0.5 mmol/L LAM （LAM-DC 0.5 mmol/L） was significantly higher than that of DC untreated with LAM （54.1 ± 4.21 vs 33.57 ± 3.14, P 〈 0.05）, and so was the expression of CD83 （20.24 ± 2.51 vs 12.83 ± 2.12, P 〈 0.05） as well as the expression of HLA-DR （74.5 ± 5.16 vs 52.8 ± 2.51, P 〈 0.05）. Compared with control group, LAM-DC group （0.5 mmol/L） secreted significantly more IL-12 （910 ± 91.5 vs 268 ± 34.3 pg/mL, P 〈 0.05）, had lower levels of IL-6 in the culture supernatant （28 ± 2.6 vs 55 ± 7.36 pg/mL, P 〈 0.05）, markedly enhanced the stimulatory capacity in the allogeneic mixed leukocyte reaction （MLR） （1.87 ± 0.6 vs 1.24 ± 0.51, P 〈 0.05）.CONCLUSION： The lower expression of phenotypic molecules and impaired allogeneic mixed lymphocyte reaction function of dendritic cells derived from patients with HBV infection could be restored in vitro by incubation with LAM.
文摘在脑卒中幸存者中,卒中后认知障碍(Post-stroke cognitive impairment,PSCI)是导致残疾的主要原因之一,目前临床治疗多聚焦于药物治疗而其他干预手段有限。经颅直流电刺激(Transcranial direct current stimulation,tDCS)是一种无创的神经调控技术,广泛用于各种认知障碍的康复治疗,但其作用机制尚不明确。本文结合近年来国内外研究,概括了PSCI发病机制、tDCS治疗认知障碍的作用机制。文献复习结果表明,tDCS可能通过改善脑部神经-血管耦合、调节皮质兴奋性、促进突触可塑性、加强脑区间的功能连接等机制达到改善PSCI的效果。这些结果可以为PSCI及卒中后其他功能障碍的临床康复治疗提供理论依据。未来,还能基于“脑-肢协同治疗技术”理论,将tDCS与其他外周干预手段相结合,使其发挥最佳疗效。
